



Universiteit
Leiden
The Netherlands

Does size matter? : bridging and dose selection in paediatric trials

Cella, M.

Citation

Cella, M. (2011, October 12). *Does size matter? : bridging and dose selection in paediatric trials*. Retrieved from <https://hdl.handle.net/1887/17924>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/17924>

Note: To cite this publication please use the final published version (if applicable).

Does size matter? Bridging and dose selection in paediatric trials

Massimo Cella

Ph.D. Thesis, Leiden University, October 2011

Does size matter?

Bridging and dose selection in paediatric trials

Proefschrift

ter verkrijging van
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof.mr. P.F. van der Heijden,
volgens besluit van het College voor Promoties
te verdedigen op woensdag 12 oktober 2011
klokke 13:45 uur

door

Massimo Cella

geboren te Lodi, Italië
in 1978

Promotor : Prof. dr. M. Danhof

Co-promotor : Dr. O.E. Della Pasqua

Referent : Prof. dr. E.M. Jacqz-Aigrain (Pharmacologie Pédiatrique
et Pharmacogénétique, Hôpital Robert Debré, Paris)

Overige Leden : Prof. dr. A. Cohen
Prof. dr. C.A. Knibbe
Prof. dr. A.P. IJzerman
Prof. dr. M. Sturkenboom (Erasmus MC, Rotterdam)

“He who is certain he knows the ending of things when he is only beginning them is either extremely wise or extremely foolish; no matter which is true, he is certainly an unhappy man, for he has put a knife in the heart of wonder”

Tad Williams

a Claudia

The research presented in this thesis was made possible by a Worldwide Development Fellowship for Post-graduate Training in Clinical Pharmacology and Discovery Medicine from GlaxoSmithKline and was performed at the Division of Pharmacology of the Leiden-Amsterdam Center for Drug Research, Leiden University, Leiden, The Netherlands.

The printing of this thesis was financially supported by:

GlaxoSmithKline
Leiden-Amsterdam Center for Drug Research

Cover design by Stefano Canti, engraving by Gustave Doré (*David slays Goliath*)
Typeset in L^AT_EX 2_ε
Printed by Optima Grafische Communicatie, Rotterdam, The Netherlands

ISBN: 978-94-6169-123-1

©2011 Massimo Cella (massimocella@hotmail.com)

No part of this thesis may be reproduced or transmitted in any form or by any means without written permission of the author.

Contents

I	Introduction	1
1	General introduction: what is the right dose for children?	13
1.1	Background	13
	Current paediatric prescription practice	14
	The correlation between dose and demographic covariates is not linear	15
	Scaling for function, not for size	16
	The future	18
1.2	Model-based paediatric drug development: regulatory and methodological aspects	20
	Bridging	22
	Allometry	24
	Non-linear mixed effects modelling	27
	Analysis of pharmacokinetic data	30
	Clinical trial simulation	33
2	Scope and intent of investigation	47
2.1	Introduction	50
2.2	Parameter estimation and uncertainty	51
2.3	Protocol implementation and trial design factors in paediatric trials	55
2.4	Conclusions and perspectives	58
II	Bridging and dosing recommendations for paediatric indications	61
3	Optimisation of PK studies in children: a non-linear mixed effects approach	63
3.1	Introduction	64
3.2	Methods	66
	One-compartment, intravenous administration	67
	One-compartment, oral absorption	68
	Two-compartment, oral absorption	68
	One-compartment with saturable elimination, oral absorption	69
	Parameter estimation and model diagnostics	69

	Optimisation of sampling frequency and intervals	70
3.3	Results	71
	One-compartment, intravenous administration	71
	One-compartment, oral absorption	72
	Two-compartment, oral absorption	73
	One-compartment with metabolic saturation, oral absorption	75
	Difference between FO and FOCE methods	76
3.4	Conclusions	76
	Limitations	77
4	A model-based approach to dose selection in paediatric development	83
4.1	Introduction	83
4.2	Methods	85
	Clinical studies	85
	Pharmacokinetic analysis	86
	Model evaluation and predictive performance	88
	Rationale for dosing regimen	88
4.3	Results	89
	Pharmacokinetic analysis	89
	Clinical relevance	92
4.4	Discussion	94
5	Are population models predictive of PK across populations?	103
5.1	Introduction	104
5.2	Methods	105
	Patients	105
	Pharmacokinetic analysis	106
	Evaluating predictive power	107
5.3	Results	109
	PK model in children (<i>Mod1</i>)	109
	PK model in infants and toddlers (<i>Mod2</i>)	110
	Extrapolation from children to infants and toddlers	111
	Extrapolation from infants and toddlers to children	113
5.4	Discussion	113
	Bridging strategies and model-based dose selection	113
	Differences in parameter-covariate correlations	116
6	The lack of interpolative power of allometric models	123
6.1	Introduction	124
6.2	Methods	126
	Patients	126
	Pharmacokinetic analysis	127
	Prediction of pharmacokinetics in children and adolescents	129
6.3	Results	129

PK model in infants, toddlers and adults (<i>model 1</i>)	129
PK model in children and adolescents (<i>model 2</i>)	131
Interpolation of midazolam exposure from infants, toddlers and adults to children and adolescents	132
6.4 Discussion	134
7 Dosing rationale for fixed-dose combinations in children	145
7.1 Introduction	146
7.2 Methods	148
Clinical studies	148
Pharmacokinetic analysis	148
Pharmacokinetic and covariate model building	149
Rationale for dosing regimen and choice of the dose ratio	151
7.3 Results	151
Pharmacokinetic analysis (adult data)	151
Pharmacokinetic analysis (pooled data)	152
Simulation scenarios and dosing recommendations	154
7.4 Discussion	156
 III Implementation and design of paediatric trials	 163
8 Dealing with heterogeneity and uncertainty in PK trials in children	165
8.1 Introduction	166
8.2 Methods	168
Rationale for the target exposure	168
Pharmacokinetic model	168
Clinical trial simulation	168
8.3 Results	171
8.4 Discussion	173
 9 Bridging strategies for drug combinations in paediatric indications	 183
9.1 Introduction	184
9.2 Methods	186
Clinical studies	186
Pharmacokinetic analysis	186
Clinical Trial Simulation (CTS)	188
9.3 Results	190
Pharmacokinetic analysis	190
Clinical Trial Simulation	191
9.4 Discussion	196

IV	Conclusions and perspectives	205
10	Summary, conclusions and perspectives	207
10.1	Regulatory framework and challenges in the transition from retrospective to prospective assessment of medicines for children.	207
10.2	Parameter estimation and uncertainty	209
10.3	Protocol implementation and trial design factors in paediatric trials	213
10.4	Perspectives	215
11	Nederlandse samenvatting (Synopsis in Dutch)	221
11.1	Introductie	223
11.2	Parameterschatting en onzekerheid	223
11.3	Adaptatieve protocollen en andere factoren in studieontwerp bij pediatrisch onderzoek	227
11.4	Conclusie en perspectief	229
	Acknowledgements	231
	Curriculum vitæ	233
	List of publications	235